热门资讯> 正文
Lucid Diagnostics在定价2500万美元股票发行后股价下跌
2025-09-10 20:29
- Lucid(LCID) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Lucid Diagnostics (NASDAQ:LUCD) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each.
- Underwriters also have a 30-day option to buy up to 3.75 million additional shares at the same price, excluding fees.
- The gross proceeds from the offering are expected to be approximately $25.0 million. The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
- The offering is expected to close on or about September 11, 2025, subject to customary closing conditions.
More on Lucid Diagnostics
- Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)
- Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript
- Lucid Diagnostics announces proposed public offering of common stock
- Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG
- Seeking Alpha’s Quant Rating on Lucid Diagnostics
推荐文章
美股机会日报 | “大空头”出手！重仓做空英伟达及Palantir；特斯拉大股东拒绝万亿美元薪酬方案
华盛早报 | 亚马逊加入OpenAI“朋友圈”，股价大涨4%创新高！分析师唱多英伟达市值上8.5万亿美元
美股机会日报 | 大摩警告！若薪酬方案被否，特斯拉或跌超10％；微软获批向阿联酋出口最新款英伟达芯片
美债上演大反攻 “Sell America”大错特错! 嘴上喊“美国例外论坍塌”的机构实际上狂买美债?
明略科技-W今日上市：香港公开发售获4452.86倍认购
新能源汽车“银十”热销 多家车企交付量破纪录
英伟达市值突破 5 万亿：回顾它与加密货币的曾经蜜月期
“股神”巴菲特旗下伯克希尔财报出炉，现金储备超3800亿美元创历史记录！速看前五大持仓
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
